US Patent 11,744,828: Tafenoquine Malaria-Prophylaxis Claims, Patent Scope and Competitive Landscape
US Patent 11,744,828 protects a specific tafenoquine prophylaxis regimen for malaria-naïve, non-G6PD-deficient patients. The core regimen is 200 mg daily for three loading days, followed by 200 mg weekly during exposure and a 200 mg post-exposure dose seven days after the final maintenance dose. The patent also claims pharmacokinetic performance, food administration, oral or sublingual delivery, tafenoquine salts, pediatric and adult use, and a corresponding dosing kit.
The claims closely track the commercial dosing concept for tafenoquine prophylaxis. The principal enforcement risk therefore concerns generic or competing products marketed, labeled, promoted, or supplied for the claimed weekly malaria-prevention regimen rather than ordinary tafenoquine manufacture alone.
What does US Patent 11,744,828 protect?
The independent method claim requires every material element below:
| Required element |
Claim requirement |
| Disease |
Prevention of symptomatic P. falciparum malaria |
| Patient |
Human subject who is malaria-naïve |
| G6PD status |
Patient does not have G6PD deficiency |
| Loading regimen |
Three doses of about 200 mg, once daily for three days |
| Timing |
Loading occurs before potential exposure |
| Maintenance regimen |
About 200 mg once weekly during potential exposure |
| First maintenance dose |
Seven days after the third loading dose |
| Post-exposure dose |
About 200 mg once, seven days after the last maintenance dose |
| Administration condition |
One or more administrations occur with food |
| Active ingredient |
Tafenoquine, a pharmaceutically acceptable salt, or a composition containing tafenoquine |
The claim is narrower than a general claim to tafenoquine malaria prophylaxis. It does not cover every tafenoquine regimen, every patient population, or every use against every malaria species.
The claim is also narrower than a composition-of-matter patent. A party that manufactures tafenoquine tablets may avoid literal infringement if it does not practice, induce, or promote the claimed regimen. A party selling tablets with instructions that reproduce the claimed dosing schedule faces a substantially higher risk.
How broad is the dosing-regimen protection?
The central commercial boundary is the combination of dose, sequence, timing, indication, patient selection and food administration.
A competing regimen may avoid literal infringement by changing one or more claim limitations, such as:
- Using a loading dose materially different from about 200 mg.
- Administering loading doses on a schedule other than once daily for three days.
- Starting maintenance treatment at a time other than seven days after the third loading dose.
- Using a maintenance dose materially different from about 200 mg.
- Omitting the post-exposure dose or administering it at a different interval.
- Targeting treatment rather than prevention.
- Targeting a malaria species or clinical use outside the claim language.
- Treating a patient who is not malaria-naïve.
- Providing a regimen for patients with G6PD deficiency, although tafenoquine safety restrictions make that commercially problematic.
- Omitting food-related instructions where the claim requires administration with food.
These design-around options are commercially constrained. Tafenoquine dosing, food effects and G6PD screening are linked to the drug's pharmacology and regulatory labeling. A generic sponsor cannot freely change the label without creating regulatory and clinical barriers.
What do dependent claims 2, 3 and 9 add?
Claims 2, 3 and 9 introduce a pharmacokinetic limitation based on minimum serum or plasma tafenoquine concentration, or Cmin.
Claims 2 and 3 differ principally in the population-level performance threshold:
| Claim |
Pharmacokinetic requirement |
| Claim 2 |
At least about 80 ng/mL before exposure and substantial maintenance throughout exposure in more than 50% of treated individuals |
| Claim 3 |
At least about 80 ng/mL before exposure and substantial maintenance throughout exposure in at least 95% of the population |
| Claim 9 |
At least about 80 ng/mL before exposure and substantial maintenance throughout exposure in the individual subject |
These limitations can strengthen infringement allegations where clinical pharmacokinetic data show that the accused regimen reliably produces the claimed concentration. They can also create validity and construction issues.
The terms "about 80 ng/mL" and "substantially maintain" require interpretation against the specification, examples and prosecution history. Claim 3 is particularly demanding because it requires performance in at least 95% of the relevant population. A sponsor would need population pharmacokinetic evidence, not merely evidence that some individuals reach the threshold.
The Cmin limitations also create proof challenges. In a commercial case, the patent owner may rely on clinical trial data, product labeling, pharmacokinetic modeling, dose instructions, or evidence that the accused regimen is bioequivalent. Direct serum testing of individual patients is not always necessary, but it would strengthen a case.
What formulations and salts are covered?
Claim 1 covers tafenoquine itself, a pharmaceutically acceptable salt, and a pharmaceutical composition containing tafenoquine. Claim 7 expressly identifies tafenoquine succinate. Claim 8 appears to cover a salt defined by a chemical structure, although the structure is not reproduced in the supplied claim text.
The claim therefore reaches the regimen when delivered through:
- Tafenoquine free base.
- Tafenoquine succinate.
- Another pharmaceutically acceptable tafenoquine salt.
- A tablet, capsule, liquid, or other pharmaceutical composition.
- Oral administration.
- Sublingual administration under claim 6.
The patent does not appear, from the supplied claims, to require a particular excipient, tablet hardness, particle size, dissolution profile, coating, manufacturing process or fixed-dose combination. It is primarily a regimen and kit patent, not a conventional formulation patent.
A separate formulation patent could still create overlapping rights if it claims a particular salt, polymorph, composition, tablet, manufacturing process or bioavailability profile.
Does US Patent 11,744,828 cover adults and children?
Yes. Claim 4 covers adults, and claim 5 covers children. Claim 1 itself is written broadly to a human subject, so the dependent claims clarify two commercially important patient groups rather than necessarily narrowing the full practical scope to those groups.
The pediatric claim does not remove the need to satisfy the 200 mg dose limitations. A pediatric product using weight-based dosing or a lower dose could avoid literal infringement if the dosage falls outside the claimed "about 200 mg" range. That approach would require separate FDA-supported dosing and pediatric safety data.
What is the relationship to FDA-approved tafenoquine products?
Tafenoquine is approved in the United States for malaria-related uses, including:
- Tafenoquine for radical cure or prevention of relapse in P. vivax malaria.
- Tafenoquine for malaria prophylaxis in travelers or other at-risk individuals, depending on the product and approved labeling.
The prophylaxis regimen relevant to US Patent 11,744,828 is commercially associated with the weekly tafenoquine product Arakoda. The approved regimen uses a three-day loading phase, weekly maintenance doses and a terminal post-exposure dose. FDA labeling also contains food-administration and G6PD-related restrictions. The product label is therefore highly relevant to infringement analysis because it may supply evidence of induced performance of the patented method (FDA, 2018a).
Krintafel is a separate tafenoquine product directed primarily to relapse prevention in P. vivax. Its indication and dosing pattern differ from the weekly prophylaxis regimen claimed in US Patent 11,744,828. A Krintafel use that does not practice the claimed malaria-prophylaxis sequence should not fall within claim 1 merely because it contains tafenoquine.
What is the Orange Book status of the patent?
A method-of-use patent can be listed in the FDA Orange Book when it claims an approved use of a drug and meets FDA listing requirements. The commercial relevance of US Patent 11,744,828 depends on whether it is listed against the applicable tafenoquine product, the use code assigned to the patent and the approved labeling associated with that listing (FDA, 2024).
The key Orange Book questions are:
| Issue |
Commercial consequence |
| Patent listed against the relevant tafenoquine NDA |
An ANDA applicant may need a patent certification |
| Use code tracks weekly malaria prophylaxis |
Paragraph IV exposure is materially increased |
| Use code is narrower than the label |
A section viii carve-out may be possible |
| Patent not listed |
The patent may still be enforceable, but Orange Book certification procedures may not apply |
| Patent expiration date |
Controls the duration of listed-patent delay and launch planning |
The supplied claim text does not establish the patent's Orange Book listing status, use code or expiration date. Those items are administrative and bibliographic data, not claim-scope conclusions.
When does US Patent 11,744,828 lose exclusivity?
The patent was granted on September 5, 2023. Its enforceable expiration date depends on the earliest effective nonprovisional priority date, any patent-term adjustment, terminal disclaimer and any applicable patent-term extension. The grant date alone does not establish the expiration date.
For US pharmaceutical patents, the baseline term is generally 20 years from the earliest effective nonprovisional filing date, subject to statutory adjustments under 35 U.S.C. §§ 154 and 156. A terminal disclaimer can shorten the term, while patent-term adjustment can lengthen it (U.S. Patent and Trademark Office, 2023).
Regulatory exclusivity is separate from patent exclusivity. Any new-drug exclusivity associated with approval does not replace the patent and does not necessarily expire on the same date. For a generic launch, the relevant barriers may include:
- Listed patents.
- FDA regulatory exclusivity.
- Patent litigation and a 30-month stay.
- Product-specific formulation or process patents.
- Manufacturing and supply constraints.
Which generic entry risks exist?
A generic tafenoquine sponsor faces different risk levels depending on the proposed label.
| Generic strategy |
Risk under US 11,744,828 |
| Label includes the three-day loading, weekly maintenance and post-exposure regimen |
High induced-infringement exposure |
| Label includes weekly prophylaxis but omits the terminal dose |
Potentially reduced literal infringement risk, subject to label and marketing conduct |
| Label directed only to P. vivax relapse prevention |
Lower risk under the supplied claims |
| Product sold without an indication but accompanied by prophylaxis promotion |
High inducement risk |
| Different dose or loading schedule |
Possible design-around, subject to equivalents and FDA feasibility |
| Tafenoquine API or tablet sale to an approved prophylaxis product |
Indirect-infringement risk depends on intent and product instructions |
| Section viii carve-out from a listed prophylaxis use |
Potentially useful, but only if the proposed label and conduct avoid the patented use |
An ANDA applicant challenging a listed patent could file a Paragraph IV certification. The patent owner could then sue within 45 days, potentially triggering the statutory 30-month stay under the Hatch-Waxman framework (21 U.S.C. § 355; Federal Trade Commission, 2013).
What validity issues affect the patent?
The strongest potential challenges would likely focus on anticipation, obviousness, written description and claim construction.
Anticipation and obviousness
The claimed regimen may be vulnerable if earlier publications disclosed the same combination of:
- Three 200 mg loading doses.
- Weekly 200 mg dosing.
- A terminal dose seven days after the final maintenance dose.
- Administration with food.
- Use in malaria-naïve, non-G6PD-deficient subjects.
Obviousness arguments could combine known tafenoquine pharmacokinetics, weekly prophylaxis studies, food-effect data and established G6PD screening requirements. The patent owner would likely argue that the particular loading sequence, concentration target and population-level pharmacokinetic performance were not predictable.
Written description and enablement
Claims 2, 3 and 9 may receive closer scrutiny because they rely on quantitative concentration and population-performance language. The specification must support the claimed 80 ng/mL threshold and the asserted maintenance rates across the claimed patient population.
Indefiniteness
Potentially contestable expressions include:
- "About 200 mg."
- "Potential exposure."
- "Substantially maintain."
- "Throughout potential exposure."
- "More than 50% of individuals."
- "95% or more of a population."
The specification, examples and prosecution history would control how a court interprets these terms. Claim 10 also contains a drafting issue: it refers to taking the post-exposure dose seven days after the "last exposure dose," while claim 1 refers to seven days after the last maintenance dose. That wording could create an interpretation dispute, particularly where exposure and maintenance schedules do not end on the same date.
What does claim 10 add through the kit?
Claim 10 covers a kit containing:
- Three approximately 200 mg loading doses.
- Multiple approximately 200 mg maintenance doses.
- One approximately 200 mg post-exposure dose.
- Instructions specifying the dosing sequence and timing.
The kit claim is commercially significant because it can reach packaging and labeling even when method-of-use proof is difficult. A kit that packages the exact quantity of loading, maintenance and post-exposure doses with matching instructions presents a strong literal-infringement case if the remaining claim elements are satisfied.
The claim does not expressly require a particular package design, calendar system, blister configuration, diagnostic test or food component. A kit containing tafenoquine without the claimed instructions may present a different analysis, although promotional materials and distribution practices remain relevant to inducement.
How strong is the patent estate for tafenoquine prophylaxis?
The estate appears strongest against a product that reproduces the approved weekly prophylaxis regimen and weakest against unrelated tafenoquine uses.
| Estate component |
Relevance |
| US 11,744,828 regimen claims |
Directly targets weekly prophylaxis with the specified sequence |
| Cmin claims |
Adds pharmacokinetic limitations and evidentiary complexity |
| Kit claim |
Targets packaged dosing programs and instructions |
| Salt and composition language |
Broadens the active-ingredient forms covered by the regimen |
| Tafenoquine composition patents |
May protect product manufacture independently |
| Formulation patents |
May affect tablet substitution and bioequivalence |
| Method-of-use patents for P. vivax |
More relevant to relapse-prevention products |
| Manufacturing patents |
Can constrain API and finished-dose supply |
The estate is commercially meaningful because the claimed schedule is closely aligned with a practical prophylaxis label. Its main weakness is that a method patent does not automatically block manufacture of tafenoquine for every indication. Enforcement depends on the accused product's label, instructions, promotional conduct and actual use.
How does tafenoquine compare with competing malaria-prevention drugs?
| Product |
Typical role |
Relationship to US 11,744,828 |
| Tafenoquine prophylaxis |
Weekly prevention with loading and post-exposure dosing |
Directly implicated |
| Atovaquone/proguanil |
Daily prevention |
Different active ingredients and schedule |
| Doxycycline |
Daily prevention |
Different active ingredient and schedule |
| Mefloquine |
Weekly prevention |
Different active ingredient |
| Primaquine |
Prevention or relapse-related use in selected settings |
Different active ingredient and G6PD considerations |
| Tafenoquine for P. vivax relapse prevention |
Single-dose or relapse-prevention use |
Different indication and regimen |
Because the patent claims tafenoquine-specific dosing, competing non-tafenoquine products do not infringe merely by competing commercially. Their relevance is market-based rather than patent-based.
Key Takeaways
- US Patent 11,744,828 is primarily a tafenoquine regimen and kit patent.
- Claim 1 requires three 200 mg loading doses, weekly 200 mg maintenance dosing, a 200 mg post-exposure dose and food administration.
- The patient must be malaria-naïve and not G6PD deficient.
- Claims 2, 3 and 9 add an approximately 80 ng/mL Cmin requirement and population or individual maintenance thresholds.
- Claim 10 targets packaged tafenoquine dosing kits with matching instructions.
- A generic label reproducing the weekly prophylaxis regimen presents the highest infringement risk.
- Tafenoquine products directed solely to P. vivax relapse prevention are less exposed under the supplied claims.
- Exact patent expiration, Orange Book listing, use code and ownership require the patent’s complete bibliographic and FDA listing records.
- The principal validity issues are anticipation, obviousness, support for the Cmin limitations and interpretation of functional terms.
- FDA labeling is central to both infringement and generic-launch analysis.
FAQs About US Patent 11,744,828
Can a generic tafenoquine manufacturer avoid this patent by changing the tablet size?
Not necessarily. The claims focus on the amount of tafenoquine administered, not the physical tablet size. A different tablet strength could still infringe if the patient receives approximately 200 mg under the claimed schedule.
Does the patent cover tafenoquine treatment after malaria infection?
The supplied claims are directed to prevention of symptomatic P. falciparum malaria before or during potential exposure. They do not expressly claim treatment of an established infection.
Does administration with food limit the scope of the patent?
Yes. Food administration is an express limitation of claim 1. The prosecution history and specification would determine whether the limitation requires every dose to be taken with food or permits the claimed "and/or" wording to apply to one or more stages of administration.
Can a generic company use a section viii statement?
Potentially, if the relevant patent is Orange Book-listed and the generic label can omit the patented prophylaxis use without encouraging the claimed regimen. The feasibility depends on the patent use code and FDA-approved labeling.
Does the patent block competing malaria drugs?
No. The supplied claims are directed to tafenoquine. Atovaquone/proguanil, doxycycline, mefloquine and other non-tafenoquine prophylaxis products fall outside the active-ingredient limitation.
References
-
Food and Drug Administration. (2018a). Arakoda (tafenoquine succinate) prescribing information. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2018b). Krintafel (tafenoquine) prescribing information. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
Federal Trade Commission. (2013). Authorized generic drugs: Short-term effects and long-term impact. U.S. Federal Trade Commission.
-
United States Patent and Trademark Office. (2023). Manual of Patent Examining Procedure, patent term adjustment and patent term extension provisions. U.S. Department of Commerce.
-
35 U.S.C. §§ 154, 156.
-
21 U.S.C. § 355.
